Cambridge, UK 3 November 2014: Horizon Discovery Group plc (LSE:HZD) (“Horizon” or “the Company”),a leading provider of research tools to support translational genomics and the development of personalized medicines, today announces the appointment of Dr David Smoller, Chief Business Officer of Horizon, as an Executive Director of the Board, with immediate effect.
David recently joined Horizon as Chief Business Officer as part of the Company’s recent acquisition of SAGE Labs for $48 million (£29 million). David, a successful serial entrepreneur, was previously Chief Executive Officer of Sage Labs, Chief Scientific Officer of Sigma-Aldrich and President of its Research Biotechnology business unit.
Before joining Sigma-Aldrich, David served as President of ProteoPlex, a seed stage spinout focusing on proteomics (acquired by Merck KGaA in 2003), and founded Genome Systems Inc. (acquired by Incyte Genomics in 1996), a company focused on providing the scientific community access to genome project-related technologies.
David has a doctorate degree in Molecular Biology and a bachelor’s degree in Biology from Emory University in Atlanta, Georgia. He also completed postdoctoral fellowships at Washington University in St. Louis Missouri, and at Monsanto Corporation.
Dr. Ian Gilham, Chairman of Horizon Discovery Group’s Board of Directors, commented: “I would like to welcome David to Horizon’s Board and I am confident that David’s deep experience in identifying and nurturing high value technologies and in building successful life sciences businesses will prove a tremendous asset as Horizon continues to grow.”
Dr David Smoller, Chief Business Officer of Horizon Discovery Group said: “The integration of SAGE Labs and Horizon is progressing well and I am delighted to be joining the Horizon Board at this exciting time for the Company.”
David Adam Smoller, age 51
Previous Directorships (held in the past five years)
SAGE Labs Inc.
Adarza Biosystems Inc.
River Pine LLC
Cultivation Capital Life Science Fund
Non Profit Advisory Boards
Academy of Science of St. Louis
National Advisory Research Council for Washington University
Center for Emerging Technologies
Board member for Washington University Biomedical Engineering Department
David Smoller holds 922,238 ordinary shares in the Company.
There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.